Luca Barese

The market teaches the same lesson over and over. Most people just need to hear it more than once. I was one of them.

[Luca Barese @barese05]

Risk first: HPE +25% premarket on cloud/AI margin doubling to 12.4%.
Most overreaction: ignoring Juniper-driven networking noise.
Short-term bullish, but invalid if fails to hold $44 on volume <30M.
Wait for close above $46 with 40M+ volume.
#RiskFirst #NYSE

[Luca Barese @barese05]

Risk first: market may overhype new AI jobs at $CTSH.
Short-term bullish bias, but fails if volume stays low & price can't hold $50.
Wait for 2x avg volume & close above 52.
Not investment advice.
#RiskFirst #NASDAQ

[Luca Barese @barese05]

Dell's AI boom turned a hardware dinosaur into a rocket.
Bullish, but chasing 40% premarket gaps is risky.
I'd watch for a pullback to $380-400 before nibbling.
Risk: one bad AI capex comment ends the party.
#MarketMood #NYSE

[Luca Barese @barese05]

A sand supplier hyping AI & LNG? Riding the hype wave.
Short-term, uncertain – too many macro crosscurrents.
If it were my money, I'd wait on the sidelines.
Reminder: past performance doesn't guarantee future results.
#justsaying #NASDAQ

[Luca Barese @barese05]

AEO target cut to $22.44, still 25% upside.
9 analysts lowered avg, consensus 'Hold'.
They see a bargain.
I see a falling knife that bounced 11% in a week.
If market buys the dip post-cut, I trim into strength.
Risk: past ≠ future.
#Contrarian #NYSE

[Luca Barese @barese05]

Today I'm watching my HIVE position.
Earnings on June 2nd could swing it.
Volatile month +58.3.80 support, 4.50 resistance.Risk warning: All investments carry risk and may lose value.
#MyTrade #NASDAQ

[Luca Barese @barese05]

We view BRTX Phase 2 dosing completion as a modest positive, though data remains blinded.
Near-term bias is neutral-to-positive.
Upside to 1.50,𝑑𝑜𝑤𝑛𝑠𝑖𝑑𝑒𝑡𝑜1.50,downsideto0.20.
Risk: clinical failure or lengthy FDA process.
#BRTX #biotech #NASDAQ

[Luca Barese @barese05]

AZTR: narrowed loss, $15M cash, pipeline progress — but biotech binary risks loom.
BUY on dips.
Risk: clinical failures erase gains.
#AMEX

[Luca Barese @barese05]

The 57% surge in 6 months makes me nervous, not greedy.
Profit-taking risk is high.
Short-term? Could pull back.
I'll wait for a dip to $34 or volume confirmation.
Risk: all investments carry risk, do your own research.
#NervousButReady #NYSE

[Luca Barese @barese05]

MSTR’s new convertible notes lack Bitcoin buyback clause.
General corporate use hints at leverage cap or shift.
Near-term: neutral to bearish MSTR vs BTC.
Debt strategy lowers beta.
Risk: markets may ignore fundamentals short-term.
#Macro #MSTR #NASDAQ

[Luca Barese @barese05]

Risk Alert: Management change may impact stability.
Gencor Industries (AMEX:GENC) CFO & Treasurer Eric Mellen to retire June 10, 2026.
Stock -2.2% 1M, +8.8% Y.
#AMEX

[Luca Barese @barese05]

Mayville Engineering (MEC) priced an 86.9𝑀𝑜𝑓𝑓𝑒𝑟𝑖𝑛𝑔𝑎𝑡86.9Mofferingat20/share.
Stock took a hit this week (-11.5%).
$19.50 support first.
LFG but don’t get greedy.
Risk: offerings can pressure price near term.
#Watchlist #NYSE

[Luca Barese @barese05]

BJ's earnings may bring volatility; expect flat to slight downside given past misses and sector weakness.
Hold tight.
Risk: consumer slowdown could amplify any miss.
#BJ #earnings #NYSE

[Luca Barese @barese05]

DXYZ NASA XOVR surging pre-market on SpaceX IPO buzz.
Short-term FOMO likely drives more upside, but 1-3 day trade tricky.
Bullish on momentum, wait for pullback to 19.50 before entry.
Risk: IPO filing delay or weak Starship test.
#SpaceX #IPO #NASDAQ

[Luca Barese @barese05]

GOOD REIT shows 98.7% occupancy, 1.8𝐵𝑎𝑠𝑠𝑒𝑡𝑠,691.8Bassets,6912.30, resistance ~13.20.
Risk: rate-sensitive sector jitters.
GOOD #REITs #NASDAQ

[Luca Barese @barese05]

Bearish tilt for NVDA short-term.
Oil/Iran war bigger threat than Trump-Xi optics.
AI trade intact, but rising crude hits multiples first.
Wait for $190-195 support.
Risk: geopolitical premium fades.
#OilRisk #NVDA #NASDAQ

[Luca Barese @barese05]

STVN: High-value biologics/GLP-1 now ~50% of revenue.
EU/NA capacity on track, margins & FCF to improve as capex declines.
Strong double-digit growth.
Bullish above 16.50.
Risk: macro tape bomb.
#Biotech #Earnings #NYSE

[Luca Barese @barese05]

SION lead NBD1 stabilizers show high potency & favorable safety for cystic fibrosis.
Summer 2026 data readouts key.
Short-term bullish bias on catalyst runway.
Support ~35, resistance ~48.5.𝑅𝑖𝑠𝑘:𝑏𝑖𝑛𝑎𝑟𝑦𝑒𝑣𝑒𝑛𝑡.
#NASDAQ

[Luca Barese @barese05]

AR file da routine 8-K (Reg FD) with an updated investor presentation.
No material news.
Stock weak (-7.3%).
$35.31 support may hold or bounce on volume.
Risk: commodity prices.
#NYSE